BIO-key International (NASDAQ:BKYI) Releases Earnings Results, Beats Estimates By $0.26 EPS

BIO-key International (NASDAQ:BKYI) issued its quarterly earnings results on Thursday. The technology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.26, FiscalAI reports. BIO-key International had a negative return on equity of 70.21% and a negative net margin of 60.59%.The firm had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.80 million.

BIO-key International Stock Performance

BKYI traded up $0.01 during trading on Thursday, hitting $3.77. 44,156 shares of the stock were exchanged, compared to its average volume of 167,494. The firm has a 50 day simple moving average of $4.36 and a 200 day simple moving average of $5.25. The firm has a market cap of $4.11 million, a price-to-earnings ratio of -0.68 and a beta of 0.44. BIO-key International has a 1 year low of $3.10 and a 1 year high of $19.70.

Analysts Set New Price Targets

A number of analysts have weighed in on BKYI shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of BIO-key International in a research note on Friday, July 17th. Zacks Research upgraded shares of BIO-key International to a “hold” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BIO-key International currently has an average rating of “Reduce”.

Hedge Funds Weigh In On BIO-key International

An institutional investor recently raised its stake in BIO-key International stock. Geode Capital Management LLC lifted its position in BIO-key International Inc. (NASDAQ:BKYI) by 49.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,892 shares of the technology company’s stock after acquiring an additional 16,271 shares during the quarter. Geode Capital Management LLC owned 0.45% of BIO-key International worth $26,000 as of its most recent SEC filing. 26.51% of the stock is currently owned by hedge funds and other institutional investors.

About BIO-key International

BIO-key International, Inc is a developer and provider of fingerprint biometric identity and access management solutions, serving enterprise and government customers. The company’s core offerings include a range of fingerprint readers and authentication software designed to verify user identity across physical and digital environments. By leveraging proprietary template-on-card and template-on-device technologies, BIO-key seeks to enhance security and streamline user access without reliance on traditional passwords.

In addition to hardware sensors, BIO-key delivers software platforms that integrate with existing IT infrastructures such as Microsoft Active Directory and major workforce management systems.